Dimensional Fund Advisors
FDMT icon

Dimensional Fund Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Dimensional Fund Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.72M Buy
730,857
+208,034
+40% +$2.03M ﹤0.01% 2315
2026
Q1 		$4.86M Buy
522,823
+227,982
+77% +$1.98M ﹤0.01% 2507
2025
Q4 		$2.21M Buy
294,841
+236,835
+408% +$2.4M ﹤0.01% 2717
2025
Q3 		$504K Buy
58,006
+2,069
+4% +$12.4K ﹤0.01% 2996
2025
Q2 		$208K Sell
55,937
-18,629
-25% -$65.5K ﹤0.01% 3111
2025
Q1 		$241K Sell
74,566
-57,399
-43% -$270K ﹤0.01% 3103
2024
Q4 		$735K Sell
131,965
-76,850
-37% -$603K ﹤0.01% 2975
2024
Q3 		$2.26M Sell
208,815
-323,927
-61% -$5.38M ﹤0.01% 2759
2024
Q2 		$11.2M Sell
532,742
-216,250
-29% -$5.42M ﹤0.01% 2214
2024
Q1 		$23.9M Buy
748,992
+54,099
+8% +$1.38M 0.01% 1892
2023
Q4 		$14.1M Buy
694,893
+24,294
+4% +$320K ﹤0.01% 2158
2023
Q3 		$8.54M Buy
670,599
+239,488
+56% +$4.01M ﹤0.01% 2339
2023
Q2 		$7.79M Buy
431,111
+284,153
+193% +$5.23M ﹤0.01% 2364
2023
Q1 		$2.53M Buy
+146,958
New +$2.86M ﹤0.01% 2678

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Dimensional Fund Advisors's FDMT Position: Q2 2026 in Review

Dimensional Fund Advisors increased its 4D Molecular Therapeutics (FDMT) stake by 40% in Q2 2026, buying an estimated $2.03M and bringing the position to 730,857 shares worth $9.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2315.

Dimensional Fund Advisors first reported a position in FDMT in Q1 2023 and has held it in 14 quarters since. The position peaked at $23.9M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Dimensional Fund Advisors held 730,857 shares of 4D Molecular Therapeutics worth $9.72M as of Q2 2026.
  • Dimensional Fund Advisors bought 208,034 4D Molecular Therapeutics shares in Q2 2026, an estimated $2.03M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2315 holding.
  • Dimensional Fund Advisors first reported a position in 4D Molecular Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Dimensional Fund Advisors's 4D Molecular Therapeutics position peaked at $23.9M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.